To highlight the systematic misidentification of phenylacetylglutamine (PAGIn) as phenylacetylglycine (PAGly) in metabolomics studies, emphasizing its implications for clinical relevance.
Key Findings:
PAG has been misidentified as PAGly in nearly half of NMR-based studies, raising concerns about the accuracy of metabolomic data.
The misidentification is due to reliance on spectral databases and careless use of data, which can lead to incorrect biological interpretations.
PAG is linked to cardiovascular risk in humans, making correct identification critical for clinical applications.
Interpretation:
The propagation of misidentification reflects broader issues in metabolomics, affecting the credibility of biomarker research and clinical applications, particularly in the context of emerging disease markers.
Limitations:
Focus primarily on NMR methods, potentially overlooking similar issues in LC-MS workflows, which may also contribute to misidentifications.
The study does not address all possible metabolites or species, which could limit the generalizability of the findings.
Conclusion:
Correcting misidentifications and validating biomarkers are essential for the credibility of metabolomics in clinical translation.
